Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease

2019 ◽  
Vol 29 (7) ◽  
pp. 929-932 ◽  
Author(s):  
Dominique Lesuisse ◽  
André Malanda ◽  
Jean-François Peyronel ◽  
Yannick Evanno ◽  
Patrick Lardenois ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Potential Treatment

scholarly journals Graphene-Based Nanoparticles as Potential Treatment Options for Parkinson’s Disease: A Molecular Dynamics Study

2020 ◽  
Vol Volume 15 ◽  
pp. 6887-6903 ◽  
Author(s):  
Ehsan Alimohammadi ◽  
Mohammad Khedri ◽  
Ahmad Miri Jahromi ◽  
Reza Maleki ◽  
Milad Rezaian
Keyword(s):  
Parkinson’S Disease ◽  
Molecular Dynamics ◽  
Parkinson's Disease ◽  
Treatment Options ◽  
Potential Treatment

The NGF superfamily of neurotrophins: Potential treatment for Alzheimer's and Parkinson's disease

1995 ◽  
Vol 18 (1) ◽  
pp. 63-65 ◽  
Author(s):  
Elliott J. Mufson ◽  
Teresa Sobreviela
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Basal Forebrain ◽  
Tyrosine Kinase Receptors ◽  
Potential Treatment ◽  
Neuron Degeneration ◽  
Cholinergic Basal Forebrain ◽  
The Family ◽  
Substantia Nigra Neuron ◽  
Tissue Grafts

AbstractStein & Glasier suggest embryonic neural tissue grafts as a potential treatment strategy for Alzheimer's and Parkinson's disease. As an alternative, we suggest that the family of nerve growth factor-related neurotrophins and their trk (tyrosine kinase) receptors underlie cholinergic basal forebrain (CBF) and dopaminergic substantia nigra neuron degeneration in these diseases, respectively. Therefore, treatment approaches for these disorders could utilize neurotrophins.

Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson’s disease

Neurocase ◽  
2013 ◽  
Vol 19 (6) ◽  
pp. 587-591 ◽  
Author(s):  
A. Hardwick ◽  
H. Ward ◽  
A. Hassan ◽  
J. Romrell ◽  
M. S. Okun
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Potential Treatment

Potential treatment of Parkinson’s disease using new-generation carbon nanotubes: a biomolecular in silico study

Nanomedicine ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. 189-204
Author(s):  
Ehsan Alimohammadi ◽  
Arash Nikzad ◽  
Mohammad Khedri ◽  
Milad Rezaian ◽  
Ahmad Miri Jahromi ◽  
...  
Keyword(s):  
Carbon Nanotubes ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Lewy Bodies ◽  
Inhibitory Effect ◽  
Strong Interactions ◽  
Amyloid Formation ◽  
Potential Treatment ◽  
Phosphorus Doped

Background: One of the underlying mechanisms of Parkinson’s disease is the aggregation of α-synuclein proteins, including amyloids and Lewy bodies in the brain. Aim: To study the inhibitory effect of doped carbon nanotubes (CNTs) on amyloid aggregation. Materials & methods: Molecular dynamics tools were utilized to simulate the influence of CNTs doped with phosphorus, nitrogen and bromine and nitrogen on the formation of α-synuclein amyloid. Results: The CNTs exhibited strong interactions with α-synuclein, with phosphorus-doped CNTs having the most substantial interactions. Conclusion: Doped-CNTs, especially phosphorus-doped carbon nanotube could effectively prevent α-synuclein amyloid formation, thus, it could be considered as a potential treatment for Parkinson’s disease. However, further in vitro and clinical investigations are required.

Sign in / Sign up

Export Citation Format

Share Document